IDiyas

For the Inventor, By the Inventor

Schliengen, Germany

Hans Peter Wessel

USPTO Granted Patents = 30 


 

Average Co-Inventor Count = 4.4

ph-index = 9

Forward Citations = 352(Granted Patents)


Location History:

  • Reichshof, DE (1979)
  • Reichshof DE (1981)
  • Heitersheim, DE (1989 - 2007)
  • Schliengen, DE (2005 - 2012)

Company Filing History:

goldMedal28 out of 4,942 
 
Hoffmann-la Roche Inc.
 patents
silverMedal2 out of 832,680 
Other
 patents

Years Active: 1979-2012

Loading Chart...
Loading Chart...
Loading Chart...
30 patents (USPTO):Explore Patents
1. 8163778 - Pyridines as FBPase inhibitors for treatment of diabetes (2012-04-24),
2. 8158655 - Sulfonamide derivatives (2012-04-17),
3. 7973051 - Aminothiazoles as FBPase inhibitors for diabetes (2011-07-05),
4. 7868030 - FBPase inhibitors for diabetes (2011-01-11),
5. 7803819 - DPP IV inhibitors (2010-09-28),
6. 7718666 - Pyrido [2,1-a] isoquinoline derivatives (2010-05-18),
7. 7314884 - DPP IV inhibitors (2008-01-01),
8. 7189756 - Pyrrolidine derivatives (2007-03-13),
9. 7071212 - N-(4-carbamimidoyl-phenyl)-glycine derivatives (2006-07-04),
10. 6861440 - DPP IV inhibitors (2005-03-01),
11. 6790860 - Pyrrolidine derivatives (2004-09-14),
12. 6683215 - N-(4-carbamimidoyl-phenyl)-glycine derivatives (2004-01-27),
13. 6548694 - N-(4-carbamimidoyl-phenyl)-glycine derivatives (2003-04-15),
14. 6476264 - N-(4-carbamimidoyl-phenyl)-glycine derivatives (2002-11-05),
15. 6242644 - N-(4-carbamimidoyl-phenyl)-glycine derivatives (2001-06-05),

Title: Hans Peter Wessel: A Visionary Inventor Shaping the Future of Technology

Introduction:

Hans Peter Wessel, a pioneering inventor based in Schliengen, DE, has made a lasting impact on the global technology landscape through his dedication to innovation and visionary problem-solving approach. With 28 patents to his name, Wessel continues to inspire future generations of inventors and innovators with his groundbreaking work.

Latest Patents:

Wessel's latest patents showcase his cutting-edge contributions to the field of pharmaceuticals and healthcare. The first patent focuses on "Pyridines as FBPase inhibitors for treatment of diabetes," introducing compounds with significant potential for the treatment of diabetes. The second patent, "Sulfonamide derivatives," highlights novel compounds that inhibit chymase and hold promise as medicaments.

Career Highlights:

Throughout his illustrious career, Wessel has made significant strides in the healthcare industry. His innovative solutions have not only advanced medical treatments but have also opened new avenues for research and development in pharmaceuticals. Wessel's expertise and ingenuity have positioned him as a key player in shaping the future of healthcare technologies.

Collaborations:

Wessel's collaborative efforts have further amplified the impact of his inventions. Working alongside talented individuals such as Kurt Hilpert and Thomas B. Tschopp, Wessel has been able to leverage diverse perspectives and expertise to bring his visionary ideas to life. These collaborations have fostered a culture of innovation and creativity, leading to groundbreaking advancements in the field.

Conclusion:

Hans Peter Wessel's unwavering dedication to innovation, coupled with his visionary approach to problem-solving, has solidified his reputation as a pioneering inventor in the global technology landscape. His profound impact on the healthcare industry and beyond serves as a testament to his exceptional talent and commitment to shaping a better future through groundbreaking inventions. Wessel's legacy will continue to inspire and empower inventors and innovators for generations to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…